The first XSeed Labs research project within Servier’s Spartners incubator in Paris-Saclay will focus on developing a new AI-empowered platform for sterically guided design of bispecific antibodies.

赛诺菲巴黎-萨克雷Spartners孵化器中的首个XSeed Labs研究项目将专注于开发一个全新的人工智能赋能平台，用于双特异性抗体的立体导向设计。

HEIDELBERG, Germany and PARIS, France, July 09, 2025 / Biotech Newswire / --

德国海德堡和法国巴黎，2025年7月9日 /生物技术新闻社/ --

BioMed X

BioMed X

, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with

，一家位于德国海德堡的独立生物医学研究所，今天宣布启动一项新计划，与

Servier

施维雅

. The two partners will implement BioMed X’s proven

双方将实施BioMed X经过验证的

XSeed Labs

种子实验室

incubator model at Servier’s research and development site in Paris-Saclay. This new

巴黎-萨克雷Servier研发基地的孵化器模型。这个新的

XSeed Labs

XSeed实验室

– the first of its kind in Europe – will be hosted at the Spartners incubator facility which is operated by BioLabs. XSeed Labs is an adaptation of BioMed X’s unique innovation model by which talented researchers are crowdsourced from the world’s leading academic institutions and embedded within the R&D facilities of pharmaceutical companies..

——欧洲首个此类项目——将由BioLabs运营的Spartners孵化器设施主办。XSeed Labs是BioMed X独特创新模式的改编版，通过该模式，从世界领先的学术机构中众包有才华的研究人员，并将其嵌入制药公司的研发设施中。

The first research project at the new XSeed Labs in collaboration with Servier is entitled “

新成立的XSeed Labs与Servier合作的第一个研究项目名为“

New AI-Empowered Platform for Sterically Guided Design of Bispecific Antibodies

新型人工智能赋能的双特异性抗体空间导向设计平台

”. It will focus on the development of an AI-driven platform that enables the rational design of bispecific antibodies by accounting for steric and structural parameters of dual target engagement.

“.它将专注于开发一个由人工智能驱动的平台，该平台通过考虑双靶点结合的空间和结构参数，实现对双特异性抗体的合理设计。”

Bispecific antibodies represent an emerging and powerful therapeutic drug class for cancer therapy, as illustrated by the clinical approval of immune cell engagers (ICE) and the upcoming generation of dual-targeting antibody-drug conjugates (ADC). However, the success of these agents may be limited by physical constraints.

双特异性抗体代表了一种新兴且强大的癌症治疗药物类别，正如免疫细胞接合器（ICE）的临床批准以及下一代双靶向抗体药物偶联物（ADC）所示。然而，这些药物的成功可能受到物理限制的影响。

The two binding arms of a bispecific antibody must simultaneously engage their targets under physiological conditions. Steric hindrance, epitope accessibility and spatial dynamics are key limiting factors that currently evade systematic design principles. There is an urgent need for innovative platforms that can rationalize and optimize bispecific antibody architecture with these constraints in mind..

双特异性抗体的两个结合臂必须在生理条件下同时与其目标结合。空间位阻、表位可及性和空间动力学是目前难以通过系统设计原则解决的关键限制因素。迫切需要创新平台来合理化并优化双特异性抗体结构，同时考虑这些限制条件。

Call for Research Project Proposals

征集研究项目提案

BioMed X and Servier are inviting research project proposals addressing the challenge of sterically guided bispecific antibody design from academic scientists worldwide. Proposals should address the following key challenges:

BioMed X 和 Servier 正在邀请全球的学术科学家提交针对空间引导双特异性抗体设计挑战的研究项目提案。提案应解决以下关键挑战：

Researchers are encouraged to submit interdisciplinary proposals that combine expertise in antibody engineering, AI/machine learning, structural biology, and immuno-oncology. Projects that demonstrate originality and translational potential will be prioritized. The new research team will join the expanding global network of BioMed X research groups operating at the interface between academia and industry..

研究人员被鼓励提交结合抗体工程、人工智能/机器学习、结构生物学和免疫肿瘤学专业知识的跨学科提案。具有原创性和转化潜力的项目将被优先考虑。这个新的研究团队将加入日益扩展的BioMed X全球研究小组网络，该网络在学术界与产业界之间的交叉领域开展工作。

Interested researchers are invited to submit their project proposals via the BioMed X Career Space at

有兴趣的研究人员可通过 BioMed X 职业空间提交他们的项目提案。

https://career.bmedx.com/call/2025-XPS-C01

https://career.bmedx.com/call/2025-XPS-C01

by

通过

August 31, 2025

2025年8月31日

.

。

“We are excited that jointly with our partner Servier, we could expand our successful XSeed Labs model to Europe,”

“我们很高兴，与我们的合作伙伴施维雅一起，我们能够将我们成功的XSeed Labs模型扩展到欧洲，”

said Dr. Christian Tidona, Founder and CEO of BioMed X.

BioMed X的创始人兼首席执行官克里斯蒂安·蒂多纳博士说。

“Following our first XSeed Labs in the US, this is a great validation of our new model, showing that early innovation by academic talents placed inside an established pharma R&D campus is indeed possible and can create significant value for a pharma company’s early R&D pipeline.”

“继我们首次在美国开展XSeed Labs之后，这对我们新模型给予了极大的验证，表明在成熟的制药研发园区内，由学术人才推动的早期创新确实可行，并能为制药公司的早期研发管道创造显著价值。”

Céline Triquel, Head of R&D Open Innovation at Servier, said:

赛琳·特里奎尔，施维雅公司研发开放创新主管，表示：

“How to innovate in the way we innovate? We are glad to launch another open innovation model at Servier: We'll have soon the great opportunity to host an XSeed Labs team at Spartners. This is a chance for our current Spartners residents to enrich their community with a different way of innovating thanks to the fantastic crowdsourcing model of BioMed X.

“我们如何在创新方式上进行创新？我们很高兴在赛诺菲推出另一种开放创新模式：我们很快将有机会在Spartners接待一支XSeed Labs团队。这对于我们现有的Spartners成员来说是一个很好的机会，可以通过BioMed X出色的众包模式，以不同的方式创新来丰富他们的社区。

This is an incredible opportunity for Servier’s R&D teams who will be in direct and close interaction with the XSeed Labs team. And finally, a chance for the patients as we invest in R&D to speed up our journey towards new therapeutic solutions in oncology.”.

这对Servier的研发团队来说是一个绝佳的机会，他们将与XSeed Labs团队进行直接且密切的互动。最后，这也是患者的一个机会，因为我们正在投资研发，以加速我们在肿瘤学领域开发新治疗方案的进程。

For high resolution please click the image.

请点击图像以获取高分辨率。

About

关于

BioMed X

BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, platform technologies, and artificial intelligence..

BioMed X 是一家独立的研究机构，在德国海德堡、美国康涅狄格州纽黑文、康涅狄格州里奇菲尔德的 XSeed 实验室以及全球范围内的合作伙伴地点设有站点。我们立足于学术界与产业界的交汇点，致力于在肿瘤学、免疫学、神经科学、平台技术以及人工智能领域开展生物医学研究和药物发现与开发。

All our research projects are supported by leading pharmaceutical companies and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research..

我们所有的研究项目都得到了领先的制药公司的支持，并由从世界各地最优秀的学校招聘的早期职业科学家开展。将全球众包与本地孵化最优秀的人才和创意相结合，使我们能够解决生物医学研究中最大的挑战。

We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.

我们致力于自由、创造性和好奇心驱动的研究，并结合对结果、时间表和交付成果的坚实验证。我们通过利用协同效应，促进跨学科的交叉融合，在推动转化生物医学方面发挥着巨大的作用。

About XSeed Labs

关于XSeed实验室

XSeed Labs is a new and scalable open innovation model which implements BioMed X’s established global crowdsourcing and local incubation processes inside pharmaceutical R&D campuses. Outstanding research talents are recruited from the best academic institutions world-wide, relocated and placed inside established commercial R&D ecosystems.

XSeed Labs 是一种新的可扩展的开放创新模式，它在制药研发园区内实施 BioMed X 已建立的全球众包和本地孵化流程。卓越的研究人才从全球最好的学术机构中招募，迁移并安置到成熟的商业研发生态系统中。

When working inside a major pharma R&D campus, they have access to industrial infrastructure and interact daily with pharma researchers and mentors while still being part of BioMed X’s global academia-style research network. The first XSeed Labs was established in 2024 on the R&D campus of Boehringer Ingelheim in Ridgefield, Connecticut..

在一家大型制药公司的研发园区内部工作时，他们可以使用工业基础设施，并每天与制药研究人员和导师互动，同时仍然是 BioMed X 全球学术风格研究网络的一部分。首个 XSeed Labs 于 2024 年在康涅狄格州里奇菲尔德的勃林格殷格翰研发园区成立。

Contact

联系

BioMed X

BioMed X

Maria Morganti

玛丽亚·莫甘蒂

VP Head of Marketing & Communications

营销与传播副总裁

+49 6221 42611 30

+49 6221 42611 30

This email address is being protected from spambots. You need JavaScript enabled to view it.

这个电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: International Cooperation; Drug Discovery; Biomedical Research; Academies and Institutes; Germany; France; BioMed X; Servier; XSeed Labs; Spartners incubator; Paris-Saclay; pharmaceutical R&D; bispecific antibodies; AI-empowered platform; sterically guided design; immune cell engagers (ICE); antibody-drug conjugates (ADC); structural data; in-silico simulation tools; dynamic modeling; structure-function analysis; antibody engineering; structural biology; early-career scientists; global research network; academia-industry interface; oncology; artificial intelligence; global crowdsourcing; early innovation; biomedical research.

关键词：国际合作；药物发现；生物医学研究；科学院与研究所；德国；法国；BioMed X；Servier；XSeed Labs；Spartners孵化器；巴黎-萨克雷；制药研发；双特异性抗体；人工智能赋能平台；空间引导设计；免疫细胞结合剂（ICE）；抗体药物偶联物（ADC）；结构数据；计算机模拟工具；动态建模；结构功能分析；抗体工程；结构生物学；早期职业科学家；全球研究网络；学术界与产业界接口；肿瘤学；人工智能；全球众包；早期创新；生物医学研究。

Source: Biotech Newswire

来源：生物技术通讯社